Jan 7, 2021   SOURCE: PR NewsWire

Global $142.2 Billion Pharmaceutical Contract Development & Manufacturing Market to 2025

DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Global Pharmaceutical Contract Development & Manufacturing Market (2020-2025) by Service, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Global Pharmaceutical Contract Development & Manufacturing Market is estimated to be USD 100 Bn in 2020 and is expected to reach USD 142.2 Bn by 2025 growing at a CAGR of 7.3%.

One of the reasons for the increase in the pharmaceutical contract development and manufacturing industry is the growth of developing biotech. Most of the companies are continuously involved in the development of complex drug compounds to address a specific disease.

Most of the companies lack the infrastructure required for formulation, clinical, and regulatory agency submission. A partnership with a pharmaceutical contract manufacturer can provide another viable option. By working cooperatively, a biotech company, a donor company, and a pharmaceutical contract manufacturer can move a product into the global markets.

The increasing level of mergers and acquisition activities are resulting in the consolidation of the contract service providers. The growth of the Pharmaceutical Contract Development and Manufacturing Market is driven by the increasing demand for generics across the globe. The increasing investment in pharmaceutical R&D by the companies pushes the growth of the market upwards.

The pharmaceutical contract development and manufacturing market are hindered by the inadequate capacity utilization of manufacturing facilities by the companies. The poor-capacity utilization of the manufacturing unit is caused due to the inefficiency of different sub-processes involved in the production process, which further results in low production. The low production is responsible for decreased revenue, thus affecting the overall pharmaceutical contract development and manufacturing market.

Dynamic changes witnessed in this sector, coupled with severe pressure over the profit margins, are anticipated to restrain growth. Stringent and complex Government regulatory requirements are also attributive to slow progress.

Scope of the Report

Based on the Service, API manufacturing services dominated the market as a result of the rising demand for High Potency Active Pharmaceutical Ingredients (HPAPI). Market players are engaged in the development of large scale manufacturing facilities on the pilot as well as commercial scale. Parenteral manufacturing services are also expected to grow significantly due to the increasing need for high levels of expertise, increasing number of sterile formulations, and growing drug development activity.

Based on end-users, the Big Pharma end-user segment is accounted for the largest share of the market. The growth of big pharma is attributed to the emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and increasing opportunities in the emerging markets.

Based on Region, North America is anticipated to have a large market share and is expected to grow significantly during the forecast period. The Asia Pacific is also expected to grow at a surplus rate due to the rise in the number of companies outsourcing projects in this region's developing economies. Heavy investments by Asian CMOs are expected for exponential progress.

Market Dynamics

Drivers

    --  Growing Demand for Generics
    --  Increasing Investments in Pharmaceutical R&D
    --  Investments in Advanced Manufacturing Technologies by CDMOs

Restraints

    --  The increasing lead time and logistics costs
    --  Strict Governmental Regulations Needed for the Approval of drugs

Opportunities

    --  Increasing Demand for Biological therapies
    --  Growing Focus on Specialty Medicines
    --  Growth in the Nuclear Medicine Sector
    --  Increasing Demand for Cell and Gene therapies

Challenges

    --  Managing Costs and Astutely Investing in Technology

Company Profiles

Some of the companies covered in this report are Thermo Fisher Scientific Inc., Catalent, Inc., Lonza Group Ltd, Recipharm AB, Vetter Pharma International GmbH, Famar Health Care Services, Abbvie Inc., Aenova Group, Consort Medical Plc, and others.

Key Topics Covered:

1. Report Description

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.3 Trends

5. Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6. Global Pharmaceutical Contract Development & Manufacturing Market, By Service
6.1 Pharmaceutical Manufacturing Services
6.1.1 Pharmaceutical API Manufacturing Services
6.1.2 Pharmaceutical FDF Manufacturing Services
6.1.3 Parenteral Manufacturing Services
6.1.4 Tablet Manufacturing Services
6.1.5 Capsule Manufacturing Services
6.1.6 Oral Liquid Manufacturing Services
6.1.7 Other Formulations
6.2 Drug Development Services
6.3 Biologics Manufacturing Services
6.3.1 Biologics API Manufacturing Services
6.3.2 Biologics FDF Manufacturing Services

7. Global Pharmaceutical Contract Development & Manufacturing Market, By End User
7.1 Big Pharma
7.2 Small & Mid-Size Pharma
7.3 Generic Pharmaceutical Companies
7.4 Other End Users

8. Pharmacy Automation Systems Market, By Geography

9. Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Competitive Scenario
9.3.1 Mergers & Acquisitions
9.3.2 Agreements, Collaborations, & Partnerships
9.3.3 New Product Launches & Enhancements
9.3.4 Investments & Fundings

10. Company Profiles
10.1 Thermo Fisher Scientific Inc.
10.2 Catalent, Inc.
10.3 Lonza Group Ltd
10.4 Recipharm AB
10.5 Veter Pharma International GmbH
10.6 Famar Healthcare Services
10.7 Abbvie Inc.
10.8 Aenova Group
10.9 Almac Group
10.10 Siegfried Holding AG
10.11 Evonik Industries AG
10.12 Boehringer Ingelheim International GmbH
10.13 Jubilant Life Sciences Ltd.
10.14 Patheon Inc.
10.15 Pfizer CentreSource
10.16 CMIC Holdings Co. Ltd
10.17 Syneos Health Inc.
10.18 LSK Global Pharma Service Co Ltd.
10.19 PAREXEL International Corporation
10.20 PRA Health Sciences Inc.
10.21 Samsung Bioepis Co. Ltd.
10.22 Sagimet Biosciences (3V Biosciences Inc.)
10.23 WuXi AppTec Inc
10.24 Quanticate Ltd.
10.25 SGS SA (SGS Life Sciences)

For more information about this report visit https://www.researchandmarkets.com/r/t4q53

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-142-2-billion-pharmaceutical-contract-development--manufacturing-market-to-2025--301202694.html

SOURCE Research and Markets